Bivalent Inhibitor Development for a Dynamic Epigenetic Tandem Reader Protein Using a Combinatorial Histone Code
Authors:
- Joseph E. McPhersonJMJoseph E. McPherson
- Molly S. SneddonMSMolly S. Sneddon
- Richard K. BegyinahRBRichard K. Begyinah
- Kesavan BabuKBKesavan Babu
- Kerstin E. PetersonKPKerstin E. Peterson
- Ryan F. FriessRFRyan F. Friess
- Thomas G. SmithTSThomas G. Smith
- Natalia Y. TretyakovaNTNatalia Y. Tretyakova
- Marcus FischerMFMarcus Fischer
- William C.K. PomerantzWPWilliam C.K. Pomerantz
Preprint
Abstract
Epigenetic readers are a class of proteins that recognize specific chemical modifications on histones to differentially regulate gene expression. Aberrant expression of readers can drive the progression of many diseases and cancers, making this protein class viable therapeutic targets. Understanding the landscape of histone modifications recognized by reader domains, and the structural mechanisms that drive these molecular recognition events, is crucial for guiding the design of pharmaceutically relevant chemical probes. BPTF contains a plant homeodomain (PHD) finger and tandem bromodomain (BRD). Here, we expand upon previous studies that found the BPTF BRD can engage acetyllysine modifications on the N-terminus of histone H3. We uncover H3K4me 3 K14ac as the specific modifications recognized by the PHD-BRD cassette, which is confirmed by crystallography. Using orthogonal methods, our work explores how these modifications can be read cooperatively, including in cis. We report the first experimental evidence proposing a ligand-induced conformational change between the two reader domains of BPTF, supporting previous computational approaches that have predicted a macromolecular rearrangement. We leverage these structural insights to rationally design a peptide-small molecule conjugate MJ-1 that inhibits both domains of BPTF and overcomes ligandability challenges associated with PHD-finger-containing proteins. The results presented here elucidate the molecular basis of the bivalent recognition of multiply modified histone H3 by BPTF and provide structural insight for developing compounds targeting the PHD finger of BPTF for therapeutic applications.Keywords
Funding Information
- National Institutes of Health (R35GM140837)
- National Institutes of Health (1T32TR004385)
- National Institutes of Health (T32GM132029.)
- National Institutes of Health (P30GM124169)
- National Institutes of Health (S10OD011952)
- National Cancer Institute (R01CA290805)
- National Institute of General Medical Sciences (P30GM133893)
- Department of Energy Office of Biological and Environmental Research (KP1605010)
This publication has 82 references indexed in Scilit:
- Differential Water Networks Guide Selectivity Optimization of a Cell Active BPTF Inhibitor in NeuroblastomaAngewandte Chemie International Edition, 2026
- High‐Affinity Peptide‐Drug Conjugate Ligands for the TRIM24 PHD and BromodomainChemistry – A European Journal, 2025
- Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo ExperimentsChemMedChem, 2023
- Evaluation of acyllysine isostere interactions with the aromatic pocket of the AF9 YEATS domainProtein Science, 2022
- A General Strategy for the Design and Evaluation of Heterobifunctional Tools: Applications to Protein Localization and Phase SeparationChemBioChem, 2022
- Methyl-Readers and Inhibitors2019
- Identifying Small‐Molecule Binding Sites for Epigenetic Proteins at Domain–Domain InterfacesChemMedChem, 2018
- The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherinJournal of Cancer Research and Clinical Oncology, 2015
- The Effect of the Length of Histone H3K4me3 on Recognition by Reader ProteinsChemBioChem, 2013
- Identification and Characterization of BPTF, a Novel Bromodomain Transcription FactorGenomics, 2000